S&P DJI Announces March 2022 Quarterly Rebalance
Filed with ASX · · 10 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Paradigm 1HY22 Key Activity Highlights
- Paradigm treats first subjects in phase 3 trial of Zilosul
- PAR reports postive topline results in heart failure model
- Preliminary Results from Phase 2 MPS I Study
- Paradigm CEO Paul Rennie to transition to Non-Exec Chairman
Later from Paradigm Biopharmaceuticals
- Clarification of recent analyst report on Patent Protection
- FDA Grants Paradigm Fast Track Designation For OA
- Paradigm Doses First US Subjects under Phase 3 trial
- Paradigm Appoints Experienced US-Based CEO
- Paradigm Receives $8.2m R&D Tax Incentive Refund
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals